Trial Search Results

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Vincristine
  • Drug: Cyclophosphamide
  • Drug: Doxorubicin
  • Drug: Prednisone
  • Drug: Bleomycin
  • Drug: Etoposide
  • Radiation: Low-dose radiotherapy (RT)

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA:

   - Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes

      - Nodular sclerosis

      - Mixed cellularity

      - Classical, not otherwise specified

   - Age ≥ 18 years and ≤ 70 years

   - Granulocytes ≥ 2 x 10e6/µL

   - Platelets ≥ 150 x 10e6/µL

   - Bilirubin ≤ 2.5 mg/dL

   - Serum creatinine ≤ 2 mg/dL

   - Patients > 50 years or those with a history of cardiac disease should have an ejection
   fraction ≥ 50%

   - All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment

   - Pathologic material reviewed at Stanford University

   - Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the
   Hodgkin's Disease Staging Conference

   - Written informed consent

EXCLUSION CRITERIA:

   - Lymphocytic predominance Hodgkin's disease

   - Prior treatment for Hodgkin's disease

   - Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter
   on a standing posteroanterior chest x-ray

   - Any lymph node mass > 10 cm in greatest trans-axial diameter

   - Two or more extranodal sites of disease

   - Constitutional (B) symptoms present at diagnosis

   - Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of
   the skin)

   - Any medical contraindication to the planned treatment, including:

      - Pregnant

      - Positive antibody test for the human immunodeficiency virus (HIV)

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Wiley
6507256432